Amisulpride의 지속 투여가 생쥐의 성별에 따른 체중 및 대사에 미치는 영향
Effects of Amisulpride administration on body weight and metabolic abnormalities in mice
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives : This study was conducted to exam the effects on food intake, body weight, and metabolic parameters by amisulpride administration in male and female mice, comparing the effects of risperidone and vehicle administration.Method : Female and male C57BL/6 mice were grouped to low dose amisulpride (1.5mg/kg), high dose amisulpride (15mg/kg), risperidone (0.1mg/kg) and vehicle. Drugs were administered once daily through intraperitoneal injection over 21days. Body weight was measured weekly and food intake was measured daily. Levels of triglyceride, glucose, insulin and prolactin were determined at the end of experiment(on day 22).Result : In female mice, low and high dose amisulpride as well as risperidone caused significant weight gains. But increases of weight gains of both amisulpride groups were numerically smaller than that of risperidone group. In male mice, only high dose amisulpride caused significant weight gain. Among weight gain groups, only weight gain of male mice with high dose amisulpride was significantly associated with increased food intake. Weight gain group in female mice did not show significant correlation with food intake. In male mice, both amisulpride groups showed significantly high plasma insulin levels compared to vehicle. In female and male mice, low and high dose amiulpride groups showed significant high plasma prolactin levels compared to vehicle. Triglyceride level were not significantly changed in all groups. Glucose level was changed significantly only in male risperidone group.Conclusion : Administration of amisulpride caused significant weight gains in female and male mice compared controls but, changes of metabolic parameters were different according to sex of mice, Our results suggest that the different mechanisms are likely to affect weight gain with amisulpride between male and female mice.
Abstract
Objectives : This study was conducted to exam the effects on food intake, body weight, and metabolic parameters by amisulpride administration in male and female mice, comparing the effects of risperidone and vehicle administration.Method : Female and male C57BL/6 mice were grouped to low dose amisulpride (1.5mg/kg), high dose amisulpride (15mg/kg), risperidone (0.1mg/kg) and vehicle. Drugs were administered once daily through intraperitoneal injection over 21days. Body weight was measured weekly and food intake was measured daily. Levels of triglyceride, glucose, insulin and prolactin were determined at the end of experiment(on day 22).Result : In female mice, low and high dose amisulpride as well as risperidone caused significant weight gains. But increases of weight gains of both amisulpride groups were numerically smaller than that of risperidone group. In male mice, only high dose amisulpride caused significant weight gain. Among weight gain groups, only weight gain of male mice with high dose amisulpride was significantly associated with increased food intake. Weight gain group in female mice did not show significant correlation with food intake. In male mice, both amisulpride groups showed significantly high plasma insulin levels compared to vehicle. In female and male mice, low and high dose amiulpride groups showed significant high plasma prolactin levels compared to vehicle. Triglyceride level were not significantly changed in all groups. Glucose level was changed significantly only in male risperidone group.Conclusion : Administration of amisulpride caused significant weight gains in female and male mice compared controls but, changes of metabolic parameters were different according to sex of mice, Our results suggest that the different mechanisms are likely to affect weight gain with amisulpride between male and female mice.
참고문헌 (25)
- Allison DB., "Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
- Batista T., "Body weight gain induced by antipsychotic drugs : mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
- Weiden PJ., "Obesity as a risk factor for antipsychotic noncompliance", Schizophr Res, 66, pp.51~57 (2004)
- Fontaine KR., "Estimating the consequences of antipsychotic induced weight gain on health and mortality rate", Psychiatry Res, 101(3), pp.277~288 (2001)
- Newcomer JW., "Metabolic considerations in the use of antipsychotic medications : a review of recent evidence", J Clin Psychiatry, 68, pp.~27 (2007)
- NCEP Expert Panel, "Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- Newcomer JW., "Second-generation(atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19, pp.1~93 (2005)
- Allison DB., "Antipsychotic-induced weight gain : a review of the literature", J Clin Psychiatry, 62, pp.22~31 (2001)
- Nasrallah H., "A review of the effect of atypical antipsychotics on weight", Psychoneuroendocrinology, 28, pp.83~96 (2003)
- Taylor DM., "Atypical antipsychotics and weight gain - a systemic review", Acta Psychiatr Scand, 101(6), pp.416~432 (2000)
- Gothelf D., "Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenc inpatients treated with olanzapine", Am J Psychiatry, 159, pp.1055~1057 (2002)
- Theisen FM., "Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine", J Neural Transm, 110, pp.111~121 (2003)
- Coccurello R., "Chronic administration of olanzapine induces metabolic and food intake alterations : a mouse model of the atypical antipsychotic-associated adverse effects", Psychopharmacology, 186, pp.561~571 (2006)
- Cope MB., "Antipsychotic drug-induced weight gain : development of an animal model", International Journal of obesity, 29, pp.607~614 (2005)
- Baptista T., "Mechanism of the neuroleptic-induced obesity in female rats", Prog Neuropsychopharmacol Biol Psychiatry, 22(1), pp.187~198 (1998)
- Baptista T., "Comparative effects of the antipsychotics sulpiride or risperidone in rats. I : Bodyweight, food intake, body composition, hormones and glucose tolerance", Brain research, 957, pp.144~151 (2002)
- Albaugh VL., "Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents", Obesity, 14, pp.36~51 (2006)
- Cooper GD., "Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormality", Journal of psychopharmacology, 21(4), pp.405~413 (2007)
- Curran MP., "Amisulpride:a review of its use in the management of schizophrenia", Drugs, 61(14), pp.2123~2150 (2001)
- Papp M., "Antidepressant-like activity of amisulpride in two animal models of depression", Journal of psychopharmacology, 14(1), pp.46~52 (2000)
- Leucht S., "Amisulpride is an "atypical" antipsychotics associated with low weight gain", Psychopharmacology, 173(1), pp.112~115 (2004)
- Papadimitriou GN., "Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient", Int Clin Psychopharmacol, 21(3), pp.181~184 (2006)
- Lacruz A., "Antipsychotic drug-induced obesity in rats : correlation between leptin, insulin and body weight during sulpride treatment", Mol Psychiat, 5, pp.70~76 (2000)
- Kim YS., "Pharmacological treatment of schizophrenia", pp.100~105 (2002), Ilchokak
- Sauvé D., "Neuroanatomical specificity of prolactin-induced hyperphgia in virgin female rats", Brain Res, 868, pp.306~314 (2002)